CPX-351 NEW
| Price | $1270 | $2550 |
| Package | 1mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-15 |
Product Details
| Product Name: CPX-351 | CAS No.: 1256639-86-7 |
| Purity: 99.76% | Supply Ability: 10g |
| Release date: 2026/05/15 |
Product Introduction
Bioactivity
| Name | CPX-351 |
| Description | CPX-351 (Vyxeos) is a liposomal formulation of cytarabine and daunorubicin with potential antitumor activity. CPX-351 delivers these two compounds to leukemia cells in a synergistic 5:1 ratio, with higher delivery rates than in normal bone marrow cells. CPX-351 is indicated for the treatment of acute myeloid leukemia. |
| In vitro | Methods: p53 wild-type AML cells (MOLM-13, MV4-11, MOLM-14) were treated with CPX-351 (62.5 nM) alone or in combination with M3814 (500 nM), and apoptosis rates were assessed at various time points using Annexin V flow cytometry. Results: M3814 significantly enhanced CPX-351-induced apoptosis in p53 wild-type AML cells, with a time-dependent increase. [2] Methods: MOLM-13 cells were co-cultured with healthy bone marrow-derived MSCs and treated with CPX-351 alone or in combination with M3814; apoptosis was assessed by Annexin V flow cytometry. Results: MSCs attenuated the apoptosis-inducing effect of CPX-351 monotherapy, whereas the combination of M3814 and CPX-351 significantly reversed the protective effect of MSCs and restored cytotoxicity against AML cells.[2] |
| In vivo | Methods: C57BL/6 mice (female, 8–10 weeks old) received tail vein injections (CPX-351 group: 12:5.3 mg/kg; “7+3” group: 600:9 mg/kg) every 3 days for a total of 3 doses. Results: The “7+3” group exhibited intestinal injury, colon shortening, inflammatory infiltration, increased permeability, and bacterial translocation. The CPX-351 group showed no such pathological changes, maintaining intestinal barrier integrity and immune function. [1] |
| Storage | Keep away from moisture,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Daunonubicin/cytarabine | Cytarabine/daunonubicin | CPX-351 |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | Anti-Cancer Clinical Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $8350.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $8.70 |
VIP6Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2026-05-28 | |
| $1.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY